TUDCA: real bile-acid biology, an approved parent drug, and a failed flagship trial

TUDCA — tauroursodeoxycholic acid — sits in an unusually awkward spot for a supplement. Its chemistry is genuinely interesting, its parent compound is an approved prescription drug with decades of use, and its highest-profile human program reached a phase 3 trial in a fatal disease. And yet the thing being sold in capsules for “mitochondrial health” and longevity rests largely on mechanism, animal work and a single small human metabolic study — while the most ambitious human bet on it ultimately failed and was pulled from the market. Both of those things are true at once, and keeping them in view is the whole point of this page.

What TUDCA actually is

TUDCA is the taurine-conjugated form of ursodeoxycholic acid (UDCA). UDCA is a naturally occurring secondary bile acid — famously abundant in bear bile, which is where the traditional use comes from — and the body conjugates bile acids with taurine or glycine to make them more water-soluble for secretion. So TUDCA is, chemically, UDCA with a taurine group attached. This matters for one reason above all: UDCA, not TUDCA, is the version that became a drug. Under the names ursodiol and ursodeoxycholic acid it is an approved medicine for dissolving certain cholesterol gallstones and, more importantly, as first-line treatment for primary biliary cholangitis (PBC), an autoimmune liver disease.^[1] TUDCA, by contrast, is sold in most of the world as a dietary supplement, not an approved drug. When you read “TUDCA is clinically proven for the liver,” the proof almost always belongs to its close relative UDCA.

The mechanism: a chemical chaperone that calms ER stress

The biology that makes TUDCA scientifically respectable is its behavior as a chemical chaperone. Inside the cell, the endoplasmic reticulum (ER) folds new proteins; when it is overwhelmed — by excess nutrients, toxins or disease — mis-folded proteins accumulate, triggering the unfolded protein response and, if unresolved, programmed cell death. TUDCA and the related chemical chaperone 4-phenylbutyrate (4-PBA) can ease this ER stress, stabilizing protein folding and blunting the apoptotic cascade. In a landmark mouse study, oral chemical chaperones including TUDCA reduced ER stress and restored glucose homeostasis in obese, diabetic mice.^[2] TUDCA also acts as a bile-acid signaling molecule and shows anti-apoptotic, cytoprotective effects across many cell and animal models. This is real, reproducible mechanistic biology — the kind that justifies serious study. It is also, crucially, mechanism, not outcome: easing ER stress in a mouse or a dish is a reason to run human trials, not a substitute for them.

Liver and cholestasis: the strongest evidence — but mostly UDCA

The hepatobiliary indications are where bile-acid therapy has its best human support. In primary biliary cholangitis, randomized controlled trials established that ursodiol improves liver biochemistry and, in long-term analyses, transplant-free survival — which is why UDCA is the standard of care.^[1] TUDCA has been studied in cholestatic liver disease too, and small comparative work suggests it is at least as well tolerated as UDCA, but the rigorous, outcome-driven trial base belongs to UDCA. So the honest grade here is: strong human evidence for the parent drug in a specific liver disease, with TUDCA riding largely on that relationship rather than on its own large trials. For a healthy person taking TUDCA as a general “liver support” supplement, neither molecule has demonstrated benefit — the trials were in people with diagnosed cholestatic disease, not as wellness prophylaxis.

Insulin sensitivity: one small, real human study

The single most-cited human TUDCA result is a small 2010 study in which four weeks of TUDCA improved hepatic and muscle insulin sensitivity in obese participants.^[3] It is a genuine, placebo-relevant human signal, and it fits neatly with the ER-stress mechanism — which is exactly why it gets quoted so often. But it should be read for what it is: a small, short, mechanisticproof-of-concept study, not a trial showing that TUDCA treats diabetes, drives weight loss, or changes any hard clinical outcome. Notably, the same study did not show improvement in adipose-tissue insulin sensitivity, underscoring that the effect was partial. One small positive study is a reason for cautious interest, not a clinical recommendation.

Neurodegeneration: the high-profile human program that failed

This is the part the supplement marketing almost never tells you, and it is the most important. TUDCA (under the name taurursodiol) was one of two active ingredients in AMX0035 — combined with sodium phenylbutyrate — developed for amyotrophic lateral sclerosis (ALS). The phase 2 CENTAUR trial reported a modest slowing of functional decline, with later analyses suggesting a possible survival benefit, and on that basis the combination was approved in the United States and Canada as Relyvrio (Albrioza in Canada).^[4] Then the confirmatory, much larger phase 3 PHOENIX trial, reported in 2024, failed to show benefit on its endpoints. Following that result, the manufacturer (Amylyx) voluntarily withdrew Relyvrio/Albrioza from the U.S. and Canadian markets in 2024.^[5]This is not a footnote: the single largest, most rigorous human test of a TUDCA-containing therapy in a disease was negative, and the product was taken off the market. Any neuroprotective claim for TUDCA has to be read against that outcome.

Eyes and other preclinical promise

TUDCA has a substantial and intriguing preclinical literature in the retina. In animal models of inherited retinal degeneration, TUDCA preserved photoreceptors and slowed degeneration — for example, conserving cone photoreceptors in a mouse model of Leber congenital amaurosis.^[6]Similar anti-apoptotic, neuroprotective signals appear across models of retinitis pigmentosa and other degenerations. This is encouraging mechanistic work and a legitimate research direction. It is also, once again, animal data — there is no approved TUDCA eye therapy and no outcome-defining human trial establishing that it protects human vision.

The longevity and “mitochondrial health” pitch

TUDCA is now marketed heavily as a longevity and mitochondrial-support supplement, often bundled with the broader anti-aging stack. The mechanistic story — reduce ER stress, limit apoptosis, support cellular resilience — is real and appealing. But there is essentially no human longevity or healthspan trial data for TUDCA. The supportive evidence is the ER-stress mechanism, the rodent metabolic and retinal work, and the one small human insulin study above. A molecule that calms a stressed cell in a dish, protects a mouse retina, or sharpens insulin signaling for four weeks has not thereby been shown to extend human healthspan. The marketing makes a leap from mechanism to outcome that the human evidence does not support — the same pattern that recurs across the longevity-supplement market.

The honest bottom line

TUDCA has more going for it than most longevity supplements: a coherent, well-characterized chemical- chaperone mechanism; a parent compound (UDCA/ursodiol) that is a real, approved drug with genuine randomized-trial support in liver disease; one small but real human insulin-sensitivity study; and a rich preclinical record in metabolism and the retina. That is a respectable foundation. But the supplement claims sprint past it. The broad “liver support,” “mitochondrial health” and longevity pitches rest on mechanism plus animal and small or short human studies — and the single most ambitious human program built on TUDCA, the ALS combination Relyvrio, failed its phase 3 trial and was withdrawn. Respect the biology and the approved parent drug; treat the longevity bottle as an unproven extrapolation.